Dr. Dreicer on the Current Role of Abiraterone and Enzalutamide in Prostate Cancer

Robert Dreicer, MD
Published: Monday, Apr 10, 2017



Robert Dreicer, MD, professor, University of Virginia Health System, discusses the current role of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) for patients with prostate cancer.

Due to the recognition of cross resistance, clinicians make a judgement to use either abiraterone or enzalutamide as the initial therapy for patients with metastatic castration-resistant prostate cancer. If a patient receives 1 agent, they don’t immediately receive the other because there is a lower likelihood of response.

Clinicians have gotten comfortable using both agents and make decisions based on what they believe is the appropriate drug to use as an initial treatment, taking all toxicities into account.
 
SELECTED
LANGUAGE


Robert Dreicer, MD, professor, University of Virginia Health System, discusses the current role of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) for patients with prostate cancer.

Due to the recognition of cross resistance, clinicians make a judgement to use either abiraterone or enzalutamide as the initial therapy for patients with metastatic castration-resistant prostate cancer. If a patient receives 1 agent, they don’t immediately receive the other because there is a lower likelihood of response.

Clinicians have gotten comfortable using both agents and make decisions based on what they believe is the appropriate drug to use as an initial treatment, taking all toxicities into account.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x